
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Reduction of Chemotherapy in Aggressive Non-Hodgkin's Lymphoma with Favorable Prognosis
140 Pages Posted: 24 Jun 2019
More...Abstract
Background: Six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) or R-CHOP-like chemotherapy are the standard treatment for aggressive B-cell non-Hodgkin's lymphoma. We hypothesized that four cycles of CHOP plus six applications of rituximab (4x R-CHOP+2xR) are non-inferior to six cycles of R-CHOP in a population with favorable prognosis.
Methods: We randomized patients 18 to 60 years of age, stage I-II disease, normal serum lactate dehydrogenase concentration, good ECOG performance status 0-1, without bulky disease (maximal tumor diameter <7.5 cm) to receive 6x R-CHOP or 4x R-CHOP+2xR. The primary endpoint was progression-free survival after three years.
Findings: After a median follow-up of 66 months, 3-years progression-free survival of patients with 4x R-CHOP+2xR was 96% (95% confidence interval [CI]: 94%; 99%), which was 3% (95% CI (one-sided): 0%; 6%) better than 6x R-CHOP, demonstrating the non-inferiority of 4x R-CHOP+2xR. Survival after 3 years was 99% (95% CI: 98% - 100%) with 4x R-CHOP+2xR versus 98% (95% CI: 96% - 99%) with 6x R-CHOP. Relapse rates were 4% (95% CI: 2% -7%) in the 4x R-CHOP+2xR group versus 5% (95% CI: 3% - 8%) in the 6x R-CHOP group, respectively.
Interpretation: In young patients with aggressive B-cell non-Hodgkin's lymphoma and favorable prognosis outcome after 4 cycles of R-CHOP is non-inferior compared to 6 cycles of R-CHOP, with relevant reduction of toxicity. Thus, chemotherapy can be reduced without compromising outcome in this population.
Trial Registration: ClinicalTrials.gov number, NCT00278421.
Funding Statement: It was coordinated by the German Study Group for high-grade Non-Hodgkin Lymphoma (DSHNHL) and funded by a German non-profit foundation, the “Deutsche Krebshilfe” (German Cancer Aid), reference number 106369.
Declaration of Interests: Referring the Work under Consideration for Publication/During the Conduct of the study: Grants: V. Poeschel: Deutsche Krebshilfe (Non-Profit/Charity Organization); H. Holte: Deutsche Krebshilfe, Roche; Personal Fees: U. Keller: Roche; Relevant financial activities outside the submitted work: Personal Fees: V. Poeschel: Hexal; G. Held: BMS, Roche, Amgen, Spectrum, MSD; A. Viardot: Roche, Kite/Gilead, Pfizer, BMS, Amgen; C. Schmidt: Novartis AG, Gilead, Takeda; L. Truemper: Takeda; U. Keller: Janssen Cilag, BMS, Gilead, Takeda, Amgen, Hexal, Celgene, Astra Zeneca, MSD; R. Marks: Roche, Servier, Merck; M. Kneba: Astra Zeneca; F. Merli: Roche, Takeda, Celgene, Janssen, Gilead, Mundipharma; P. de Nully Brown: Roche; F. Hartmann: BMS, Roche, Boehringer Ingelheim, Sanofi, Celgene, Novartis, Ipsen, Janssen, Gilead; S. Stilgenbauer: Abbvie, Amgen, Astra Zeneca, Celgene, Gilead, GSK, Roche, Janssen, Novartis, Pharmacyclics, Sunesis; Grants: V. Poeschel: Abbvie, Amgen, Roche; G. Held: BMS, Roche; C. Schmidt: Janssen Cilag, Gilead, Takeda; S. Stilgenbauer: Abbvie, Amgen, Astra Zeneca, Celgene, Gilead, GSK, Roche, Janssen, Novartis, Pharmacyclics, Sunesis; Non-financial support: C. Schmidt: Janssen Cilag, Gilead, Takeda; F. Merli: Takeda, Celgene; S. Stilgenbauer: Abbvie, Amgen, Astra Zeneca, Celgene, Gilead, GSK, Roche, Janssen, Novartis, Pharmacyclics, Sunesis All other authors declared no conflicts of interest.
Ethics Approval Statement: The study was conducted in accordance with the Helsinki declaration. The protocol and its amendments were approved by the ethics committee of each participating center.
Suggested Citation: Suggested Citation